← Human Trials & Peer-Reviewed Studies
Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study.
Plain-language guide to PMID 35807864 (2022): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 35807864
- Journal
- Nutrients
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Rendina D et al. (13 authors)
- DOI
- 10.3390/nu14132683
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension.
In addition to this clinical trial, the researchers also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively.
Who Took Part
Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort).
The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control.
What Was Measured
In addition to this clinical trial, the researchers also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively.
Topics PubMed links to this paper include Calcitriol, Cardiovascular Diseases, Cholecalciferol, Cholesterol, Dietary Supplements, HEK293 Cells and Heart Disease Risk Factors.
The authors tagged it with the keywords clinical trial, hypertension, hypovitaminosis D, inflammation and miR-21.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The publication is from 2022 (Nutrients), a journal based in Switzerland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.